An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study in healthy male subjects. The study will have 2
phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will
consist of a Screening Period and a Baseline Period, during which each subject's study
eligibility will be determined and baseline assessments will be conducted.